Difference between revisions of "Apixaban (Eliquis)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Venous thromboembolism (VTE) medications" to "Category:Venous thromboembolism medications") |
Warner-admin (talk | contribs) m (Text replacement - "[[Venous thromboembolism (VTE)" to "[[Venous_thromboembolism") |
||
| Line 11: | Line 11: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*Atrial fibrillation | *Atrial fibrillation | ||
| − | *[[ | + | *[[Venous_thromboembolism]] |
==Patient drug information== | ==Patient drug information== | ||
| Line 19: | Line 19: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*12/28/2012: FDA approved "to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem."<ref>[http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation (FDA.gov)]</ref> | *12/28/2012: FDA approved "to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem."<ref>[http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation (FDA.gov)]</ref> | ||
| − | *3/13/2014: FDA approved "for the prophylaxis of [[ | + | *3/13/2014: FDA approved "for the prophylaxis of [[Venous_thromboembolism|deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE)]], in patients who have undergone hip or knee replacement surgery." |
| − | *8/21/2014: FDA approved "for the treatment of [[ | + | *8/21/2014: FDA approved "for the treatment of [[Venous_thromboembolism|DVT and PE]], and for the reduction in the risk of [[Venous_thromboembolism|recurrent DVT and PE]] following initial therapy." |
==Also known as== | ==Also known as== | ||
Revision as of 18:44, 31 July 2019
General information
Class/mechanism: Selective and reversible factor Xa inhibitor. By inhibiting free and clotbound factor Xa in the coagulation cascade, apixaban inhibits prothrombinase activity, the conversion of prothrombin to thrombin, and the subsequent conversion of fibrinogen to fibrin. It does not need antithrombin III to exert its antithrombotic activity.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Reversal information
Factor Xa, recombinant, inactivated-zhzo (Andexxa) can bind, sequester, and reverse the anticoagulation effect of rivaroxaban and apixaban.
Diseases for which it is used
- Atrial fibrillation
- Venous_thromboembolism
Patient drug information
History of changes in FDA indication
- 12/28/2012: FDA approved "to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem."[5]
- 3/13/2014: FDA approved "for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery."
- 8/21/2014: FDA approved "for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy."
Also known as
- Brand name: Eliquis
References
- ↑ 1.0 1.1 1.2 Apixaban (Eliquis) package insert
- ↑ Apixaban (Eliquis) package insert (locally hosted backup)
- ↑ Eliquis manufacturer's website
- ↑ Apixaban (Eliquis) patient drug information (UpToDate)
- ↑ FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation (FDA.gov)